CS
DNA.WS

Credit Suisse’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Credit Suisse’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-220
Closed -$44 – 3807
2022
Q4 		$44 Hold
220
– – ﹤0.01% 3634
2022
Q3 		$0 Hold
220
– – ﹤0.01% 4377
2022
Q2 		$0 Buy
+220
New +$140 ﹤0.01% 4419

Other funds holding DNA.WS

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
JRCM
Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Credit Suisse's DNA.WS Position: Q1 2023 in Review

Credit Suisse sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q1 2023, closing a stake of 220 shares — an estimated $44 sold.

Credit Suisse first reported a position in DNA.WS in Q2 2022 and held it in 3 quarters. The position peaked at $44 in Q4 2022. 40 funds tracked by Wall St. Rank hold DNA.WS as of Q1 2023.

  • Credit Suisse reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 220 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q1 2023, an estimated $44.
  • Credit Suisse first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $44 in Q4 2022.
  • 40 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.